Summary:
In adults with type 1 diabetes, metformin (1500 mg daily for 26 weeks) did not significantly reduce hepatic insulin resistance compared to placebo, though it was associated with no increase in hypoglycemia or ketoacidosis.
| PICO | Description |
|---|---|
| Population | Adults with type 1 diabetes (n = 40), assessed for insulin resistance compared to adults without diabetes (n = 20); 37 participants with type 1 diabetes completed a 26-week randomized controlled trial. |
| Intervention | Metformin 1500 mg daily for 26 weeks, with evaluation of insulin resistance via hyperinsulinemic-euglycemic clamp technique. |
| Comparison | Placebo for 26 weeks in adults with type 1 diabetes. |
| Outcome | No significant difference in reduction of endogenous glucose production (EGP) between metformin and placebo groups (mean difference 0.2 µmol/kg FFM/min; 95% CI, -0.4 to 0.8; p = 0.53). No increase in hypoglycemia or diabetic ketoacidosis observed in either group. |
Source: Snaith, Jennifer R., et al. “Effect of metformin on insulin resistance in adults with type 1 diabetes: a 26-week randomized double-blind clinical trial.” Read article here.
